Firebrick Pharma targets global expansion as Nasodine sales surge in U.S. and Asia

An announcement from Firebrick Pharma Limited ( (AU:FRE) ) is now available.

Firebrick Pharma has reported strong momentum for its Nasodine portfolio, highlighting robust sales growth in the U.S. and Singapore and signalling a transition from early adoption to the growth phase for Nasodine Nasal Spray. The company has disclosed that U.S. winter sales rose 275% and customer numbers grew 168%, and it expects overall sales to double in calendar 2026 as distribution and product uptake widen.

Management outlined an ambitious expansion roadmap, including the launch of a third Nasodine product in 2026 and anticipated approvals in the Philippines and two other regional markets. Over the next three years, Firebrick plans to add a fourth product to the Nasodine range and is targeting approvals or sales of at least one Nasodine product in up to 10 countries, a strategy that could materially strengthen its international footprint and revenue base.

The most recent analyst rating on (AU:FRE) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Firebrick Pharma Limited stock, see the AU:FRE Stock Forecast page.

More about Firebrick Pharma Limited

Firebrick Pharma Limited is an Australian pharmaceutical company focused on developing and commercialising novel formulations and uses of povidone-iodine. Its lead product, Nasodine Nasal Spray, has been launched in the United States, Singapore, and Fiji & South Pacific, with a follow-on Nasodine Throat Spray now available in Singapore and Fiji. The company is targeting further regulatory approvals in additional markets, including the Philippines, as it builds a broader Nasodine-branded portfolio.

Average Trading Volume: 68,820

Technical Sentiment Signal: Hold

Current Market Cap: A$13.89M

Learn more about FRE stock on TipRanks’ Stock Analysis page.